A Retrospective Analysis of Corticosteroid Utilization Before Initiation of Biologic DMARDs Among Patients with Rheumatoid Arthritis in the United States
Open accessThe DOI matches its Crossref record; 34 of the 35 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Understanding the effects of corticosteroid utilization prior to initiation of biologic disease-modifying antirheumatic drugs (DMARDs) can inform decision-makers on the appropriate use of these medications. This study examined treatment patterns and associated burden of corticosteroid utilization before initiation of biologic DMARDs among rheumatoid arthritis (RA) patients. METHODS: A retrospective analysis was conducted of adult RA patients in the US MarketScan Database (2011-2015). The following patterns of corticosteroid utilization were analyzed: whether corticosteroids were used; duration of use (short/long duration defined as < or ≥ 3 months); and dosage (low as < 2.5, medium as 2.5 to < 7.5 and high as ≥ 7.5 mg/day). Effects of corticosteroid use on time to biologic DMARD initiation were examined using Cox proportional hazards models. Likelihood and number of adverse events were examined using logistic and negative binomial regression models. Generalized linear models were used to examine healthcare costs. Independent variables in all models included patient demographics and health characteristics. RESULTS: A total of 25,542 patients were included (40.84% used corticosteroids). Lower hazard of biologic DMARD initiation was associated with corticosteroid use (hazard ratio = 0.89, 95% confidence interval = 0.83-0.96), long duration and lower dose. Corticosteroid users compared to non-users had higher incidence rates of various adverse events including cardiovascular events (P < 0.05). Higher likelihood of adverse events was associated with corticosteroid use and long duration of use, as was increased number of adverse events. Corticosteroid users had a greater annualized mean number of physician visits, hospitalizations, and emergency department (ED) visits than non-users in adjusted analysis. Corticosteroid users compared to non-users had higher mean costs for total healthcare, physician visits, hospitalizations, and ED visits. CONCLUSIONS: Among patients with RA, corticosteroid utilization is associated with delayed initiation of biologic DMARDS and higher burden of adverse events and healthcare utilization/costs before the initiation of biologic DMARDs. FUNDING: AbbVie Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Additional studies have corroborated these findings, linking even low dose glucocorticoid use (prednisone 2.5-7.5 mg/day) to increased risks of cardiovascular disease (9), severe infections (10), hypertension (11), diabetes (12), osteoporosis and fractures (13, 14), and increased overall mortality with concurrent type 2 diabetes mellitus (15).”
From European Society of Endocrinology and Endocrine Society Joint Clinical Guideline: Diagnosis and Therapy of Glucocorticoid-induced Adrenal Insufficiency (2024) · cites this paper as [9]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90171-8 · Cited by 49,742
Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases
DEYO, R. (1992) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(92)90133-8 · Cited by 10,452
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
Singh, J. A., Saag, K. G., Bridges, S. L., Akl, E. A., Bannuru, R. R., Sullivan, M. C., Vaysbrot, E., McNaughton, C., Osani, M., Shmerling, R. H., et al. (2016) · Arthritis & Rheumatology · doi:10.1002/art.39480 · Cited by 2,777
Smolen, J. S., Landewé, R., Bijlsma, J., Burmester, G., Chatzidionysiou, K., Dougados, M., Nam, J., Ramiro, S., Voshaar, M., van Vollenhoven, R., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210715 · Cited by 2,057
Smolen, J. S., Breedveld, F. C., Burmester, G. R., Bykerk, V., Dougados, M., Emery, P., Kvien, T. K., Navarro-Compán, M. V., Oliver, S., Schoels, M., et al. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-207524 · Cited by 1,465
Gelberg, L., Andersen, R. M., & Leake, B. D. (2000) · PubMed · Cited by 1,257
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
Singh, J. A., Saag, K. G., Bridges, S. L., Akl, E. A., Bannuru, R. R., Sullivan, M. C., Vaysbrot, E., McNaughton, C., Osani, M., Shmerling, R. H., et al. (2016) · Arthritis Care & Research · doi:10.1002/acr.22783 · Cited by 1,107
Oral corticosteroids and fracture risk: relationship to daily and cumulative doses
van Staa, T. P., Leufkens, H. G. M., Abenhaim, L., Zhang, B., & Cooper, C. (2000) · Rheumatology · doi:10.1093/rheumatology/39.12.1383 · Cited by 696 · cited 1×
“Corticosteroid utilization measures were as follows: having used corticosteroids or not, treatment duration, and dosage [18, 19].”
MethodPopulation‐based assessment of adverse events associated with long‐term glucocorticoid use
Curtis, J. R., Westfall, A. O., Allison, J., Bijlsma, J. W., Freeman, A., George, V., Kovac, S. H., Spettell, C. M., & Saag, K. G. (2006) · Arthritis Care & Research · doi:10.1002/art.21984 · Cited by 595
Saag, K. G., Koehnke, R., Caldwell, J. R., Brasington, R., Burmeister, L. F., Zimmerman, B., Kohler, J. A., & Furst, D. E. (1994) · The American Journal of Medicine · doi:10.1016/0002-9343(94)90131-7 · Cited by 540
Use of oral corticosteroids in the United Kingdom
van Staa, T. P. (2000) · QJM · doi:10.1093/qjmed/93.2.105 · Cited by 529 · cited 1×
“Corticosteroid utilization measures were as follows: having used corticosteroids or not, treatment duration, and dosage [18, 19].”
Methodvan Everdingen, A. A., Jacobs, J. W. G., Siewertsz van Reesema, D. R., & Bijlsma, J. W. J. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-136-1-200201010-00006 · Cited by 489
Potency and duration of action of glucocorticoids
Meikle, A. W., & Tyler, F. H. (1977) · The American Journal of Medicine · doi:10.1016/0002-9343(77)90233-9 · Cited by 319
Corticosteroid-induced clinical adverse events: frequency, risk factors and patient?s opinion
Fardet, L., Flahault, A., Kettaneh, A., Tiev, K. P., Généreau, T., Tolédano, C., Lebbé, C., & Cabane, J. (2007) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2007.07950.x · Cited by 273
Panoulas, V. F., Douglas, K. M. J., Stavropoulos-Kalinoglou, A., Metsios, G. S., Nightingale, P., Kita, M. D., Elisaf, M. S., & Kitas, G. D. (2008) · Rheumatology · doi:10.1093/rheumatology/kem311 · Cited by 193 · cited 1×
“5 mg, and found that longterm use of medium-dose corticosteroid therapy was associated with an increased prevalence of hypertension in RA patients compared to low dose and no use groups [32].”
BackgroundSchmajuk, G., Trivedi, A. N., Solomon, D. H., Yelin, E. H., Trupin, L. S., Chakravarty, E. F., & Yazdany, J. (2011) · JAMA · doi:10.1001/jama.2011.67 · Cited by 132 · cited 1×
“To be included, a patient had to have at least two diagnoses of RA at least a week apart within a year in an ambulatory or non-acute setting [9, 13, 14].”
BackgroundCorticosteroid use in rheumatoid arthritis: prevalence, predictors, correlates, and outcomes.
Caplan, L., Wolfe, F., RUSSELL, A. S., & Michaud, K. D. (2007) · PubMed · Cited by 127
Treatment of older adult patients diagnosed with rheumatoid arthritis: Improved but not optimal
Schmajuk, G., Schneeweiß, S., Katz, J. N., Weinblatt, M. E., Setoguchi, S., Avorn, J., Levin, R., & Solomon, D. H. (2007) · Arthritis Care & Research · doi:10.1002/art.22890 · Cited by 122 · cited 1×
“To be included, a patient had to have at least two diagnoses of RA at least a week apart within a year in an ambulatory or non-acute setting [9, 13, 14].”
BackgroundHarrold, L. R., Harrington, J. T., Curtis, J. R., Furst, D. E., Bentley, M. J., Shan, Y., Reed, G., Kremer, J. M., & Greenberg, J. D. (2011) · Arthritis & Rheumatism · doi:10.1002/art.33380 · Cited by 67
Low-dose corticosteroid therapy in rheumatoid arthritis: Balancing the evidence
Saag, K. G. (1997) · The American Journal of Medicine · doi:10.1016/s0002-9343(97)90006-1 · Cited by 57
Next stage of RA treatment: is TNF inhibitor-free remission a possible treatment goal?
Tanaka, Y. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-202350 · Cited by 56 · cited 1×
“If disease activity remains moderate to severe, biologic DMARDs are recommended as monotherapy or combination therapy with non-biologic DMARDs as they have substantially changed the course of disease and dramatically improved long-term outcomes in RA among patients refractory or intolerant to traditional DMARDs [1, 4].”
BackgroundSecond-Line Agents in the Treatment of Rheumatic Diseases
(1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-6-542_4 · Cited by 54
Oxford Handbook of Critical Care
Singer, M., & Webb, A. (2009) · doi:10.1093/med/9780199235339.001.0001 · Cited by 49
Pincus, T., Sokka, T., Castrejón, I., & Cutolo, M. (2013) · Arthritis Care & Research · doi:10.1002/acr.21899 · Cited by 42 · cited 2×
“This seemingly contradicts recent studies of corticosteroids in RA treatment suggesting that low dosage (even in the long-term) may result in non-significant, limited or mild adverse events [5, 6, 31].”
BackgroundResultChen, S., Choi, C., Li, Q., Yeh, W., Lee, Y., Kao, A. H., & Liang, M. H. (2015) · Arthritis Care & Research · doi:10.1002/acr.22574 · Cited by 42
Santiago, T., & da Silva, J. A. P. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12428 · Cited by 40
STUART, B., Doshi, J. A., Briesacher, B. A., Wrobel, M. V., & Baysac, F. (2004) · Clinical Therapeutics · doi:10.1016/j.clinthera.2004.10.012 · Cited by 38
Kim, G., Barner, J. C., Rascati, K. L., & Richards, K. M. (2015) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2015.21.5.401 · Cited by 27
Haraoui, B. P., Jovaisas, A. V., Bensen, W., Faraawi, R., Kelsall, J., Dixit, S., Rodrigues, J. F., Sheriff, M., Rampakakis, E., Sampalis, J. S., et al. (2015) · RMD Open · doi:10.1136/rmdopen-2015-000078 · Cited by 24 · cited 1×
“found that, compared to non-corticosteroid users, risk of infection was significantly increased among RA patients who used corticosteroids at either lower doses (B 5 mg) or higher doses ([5 mg) [33].”
ResultSafety of Glucocorticoids in Rheumatoid Arthritis: Evidence from Recent Clinical Trials
Santiago, T., & da Silva, J. A. P. (2014) · NeuroImmunoModulation · doi:10.1159/000362726 · Cited by 24 · cited 2×
“This point is reinforced by Santiago and da Silva who cautioned that the quantity and ‘‘especially the quality of evidence are too limited to establish conclusions’’ concerning the safety of low-dose corticosteroid use in RA [31].”
BackgroundResultOxford Handbook of Critical Care
Webster, N. R. (2005) · British Journal of Anaesthesia · doi:10.1093/bja/aei603 · Cited by 24
Emery, P., Solem, C. T., Majer, I. M., Cappelleri, J. C., & Tarallo, M. (2015) · Rheumatology International · doi:10.1007/s00296-015-3312-3 · Cited by 23 · cited 1×
“noted that early initiation of biologic DMARDs was associated with improved outcomes and decreased hospitalizations [30].”
BackgroundReceipt of Glucocorticoid Monotherapy Among Medicare Beneficiaries With Rheumatoid Arthritis
Yazdany, J., Tonner, C., Schmajuk, G., Lin, G. A., & Trivedi, A. N. (2014) · Arthritis Care & Research · doi:10.1002/acr.22312 · Cited by 23 · cited 3×
“To be included, a patient had to have at least two diagnoses of RA at least a week apart within a year in an ambulatory or non-acute setting [9, 13, 14].”
BackgroundResultTHU0180 Time to Biologic Therapy Driven by Rheumatoid Arthritis Disease Activity and Severity
Harrold, L. R., Greenberg, J. D., Bao, Y., Grant, S., Kremer, J. M., Reed, G., Florentinus, S. R., Karki, C. K., Lacerda, A. P., & Ganguli, A. X. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-eular.1161 · Cited by 3 · cited 1×
“Another study found that median time from initiation of the traditional DMARD to the first biologic was more than 4 years [8].”
BackgroundSelf-citation
Cited by
Beuschlein, F., Else, T., Bancos, I., Hahner, S., Hamidi, O., van Hulsteijn, L., Husebye, E. S., Karavitaki, N., Prete, A., Vaidya, A., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae250 · Cited by 172
Beuschlein, F., Else, T., Bancos, I., Hahner, S., Hamidi, O., van Hulsteijn, L. T., Husebye, E. S., Karavitaki, N., Prete, A., Vaidya, A., et al. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae029 · Cited by 157
Pernicova, I., Kelly, S., Ajodha, S., Sahdev, A., Bestwick, J. P., Gabrovska, P., Akanle, O., Ajjan, R., Kola, B., Stadler, M., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30021-8 · Cited by 89
An updated review of glucocorticoid-related adverse events in patients with rheumatoid arthritis
Luís, M., Freitas, J., Costa, F. C., Buttgereit, F., Boers, M., Da Silva, J. A. P., & Santiago, T. (2019) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2019.1615052 · Cited by 49
“This observation may be partly explained by perimortal bias, since patients with terminal illness are more likely to be prescribed with GC both as part of cancer therapy and as a substitute for other DMARDs.”
BackgroundInfluentialBiologic and Glucocorticoid Use after Methotrexate Initiation in Patients with Rheumatoid Arthritis
George, M., Sauer, B. C., Teng, C., Cannon, G. W., England, B. R., Kerr, G. S., Mikuls, T. R., & Baker, J. F. (2018) · The Journal of Rheumatology · doi:10.3899/jrheum.180178 · Cited by 29
Metadata
- Authors
- Spivey, C. A., Griffith, J., Kaplan, C., Postlethwaite, A., Ganguli, A., & Wang, J.
- Affiliations
- University of Tennessee Health Science Center (US)
- AbbVie (United States) (US)
- Corresponding author
- Wang, Junling
- Venue
- Rheumatology and Therapy
- Published
- 2017-12-04
- Volume
- 5
- Issue
- 1
- Pages
- 255-270
- ISSN
- 2198-6576 (ISSN-L)
- 2198-6584
- PMC
- PMC5935609
- OpenAlex
- W2774815752
- Cited by
- 20
- References
- 35
- Citations by year
- 2026: 2 · 2024: 3 · 2023: 1 · 2022: 2 · 2021: 5 · 2020: 1 · 2019: 3 · 2018: 3
- FWCI
- 1.67
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- Locations
- Rheumatology and Therapy (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- AbbVie
- Topics
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Health Sciences › Medicine › Hematology › Autoimmune and Inflammatory Disorders Research
- Health Sciences › Medicine › Complementary and alternative medicine › Natural Compounds in Disease Treatment
- Keywords
- rheumatoid arthritis, corticosteroids, biologic DMARDs, treatment patterns, corticosteroid adverse effects, cardiovascular events, health care utilization, health care costs, corticosteroid dose and duration
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.